Cargando…
Valproic acid improves second-line regimen of small cell lung carcinoma in preclinical models
With 5-year survival rates below 5%, small cell lung carcinoma (SCLC) has very poor prognosis and requires improved therapies. Despite an excellent overall response to first-line therapy, relapses are frequent and further treatments are disappointing. The goal of the study was to improve second-line...
| Autores principales: | , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
European Respiratory Society
2015
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5005116/ https://www.ncbi.nlm.nih.gov/pubmed/27730151 http://dx.doi.org/10.1183/23120541.00028-2015 |